Kadmon Holdings Company Profile (NASDAQ:KDMN)

About Kadmon Holdings

Kadmon Holdings logoKadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KDMN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.59
  • 50 Day Moving Average: $4.29
  • 200 Day Moving Average: $6.21
  • 52-Week Range: $3.49 - $11.73
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.47
  • P/E Growth: 0.00
  • Market Cap: $161.83M
  • Outstanding Shares: 45,078,000
Additional Links:

Analyst Ratings

Consensus Ratings for Kadmon Holdings (NASDAQ:KDMN) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $14.10 (292.76% upside)

Analysts' Ratings History for Kadmon Holdings (NASDAQ:KDMN)
Show:
DateFirmActionRatingPrice TargetDetails
2/1/2017HC WainwrightReiterated RatingBuy$25.00View Rating Details
11/21/2016JMP SecuritiesReiterated RatingBuyView Rating Details
11/10/2016Jefferies Group LLCReiterated RatingBuy$12.00 -> $10.00View Rating Details
8/22/2016Citigroup Inc.Initiated CoverageNeutral$12.00View Rating Details
8/1/2016WBB SecuritiesInitiated CoverageSell$7.50View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Kadmon Holdings (NASDAQ:KDMN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016        
11/9/2016Q3 2016($0.40)($4.23)$3.90 million$5.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kadmon Holdings (NASDAQ:KDMN)
Current Year EPS Consensus Estimate: $-10.63 EPS
Next Year EPS Consensus Estimate: $-2.44 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.93)($0.93)($0.93)
Q3 20161($0.90)($0.90)($0.90)
Q4 20161($0.57)($0.57)($0.57)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Kadmon Holdings (NASDAQ:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kadmon Holdings (NASDAQ:KDMN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2016Harlan WaksalCEOBuy2,000$6.37$12,740.00View SEC Filing  
11/14/2016Harlan WaksalCEOBuy2,000$6.79$13,580.00View SEC Filing  
11/11/2016Konstantin PoukalovCFOBuy4,000$5.81$23,240.00View SEC Filing  
9/14/2016Daniel S LoebMajor ShareholderBuy19,611$7.79$152,769.69View SEC Filing  
9/13/2016Daniel S LoebMajor ShareholderBuy68,654$8.33$571,887.82View SEC Filing  
9/6/2016Daniel S LoebMajor ShareholderBuy81,781$9.39$767,923.59View SEC Filing  
8/26/2016Daniel S LoebMajor ShareholderBuy32,916$9.98$328,501.68View SEC Filing  
8/22/2016Daniel S LoebMajor ShareholderBuy11,305$10.00$113,050.00View SEC Filing  
8/15/2016Daniel S LoebMajor ShareholderBuy6,010$9.95$59,799.50View SEC Filing  
8/12/2016Daniel S LoebMajor ShareholderBuy87,529$9.98$873,539.42View SEC Filing  
8/5/2016Daniel S LoebMajor ShareholderBuy66,828$9.94$664,270.32View SEC Filing  
8/3/2016Daniel S LoebMajor ShareholderBuy1,431,996$11.35$16,253,154.60View SEC Filing  
8/1/2016Goldentree Asset Management LpMajor ShareholderBuy208,333$12.00$2,499,996.00View SEC Filing  
7/28/2016Bart M SchwartzDirectorBuy2,000$9.77$19,540.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kadmon Holdings (NASDAQ:KDMN)
DateHeadline
News IconThe Analysts Set Kadmon Holdings Inc (KDMN) Target Price at $13.63 - Petro Global News 24 (NASDAQ:KDMN)
petroglobalnews24.com - February 25 at 8:32 AM
News IconLooking Ahead for Kadmon Holdings Inc (NYSE:KDMN); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:KDMN)
aikenadvocate.com - February 22 at 6:20 PM
4-traders.com logoMOAF Ministry of Agriculture and Forests of Bhut : Selected candidates for the Post of Farm Labourers (NASDAQ:KDMN)
www.4-traders.com - February 20 at 10:27 AM
News IconCould Kadmon Holdings Inc (KDMN) Gain Strenght? The Stock Reaches 1 Year Low - The Randolph Guide (NASDAQ:KDMN)
randolphguide.com - January 30 at 6:50 PM
4-traders.com logoKADMON HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:KDMN)
www.4-traders.com - January 18 at 6:38 PM
News IconStock Tracker: Earnings & Estimates for Kadmon Holdings Inc (NYSE:KDMN) - Aiken Advocate (NASDAQ:KDMN)
aikenadvocate.com - January 18 at 6:38 PM
marketexclusive.com logoKadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors ... - Market Exclusive (NASDAQ:KDMN)
marketexclusive.com - January 11 at 6:45 PM
insidermonkey.com logoIs Aratana Therapeutics Inc (PETX) A Good Stock To Buy? (NASDAQ:KDMN)
www.insidermonkey.com - December 13 at 11:35 PM
insidermonkey.com logoHedge Funds Are Buying Kadmon Holdings LLC (KDMN) (NASDAQ:KDMN)
www.insidermonkey.com - December 13 at 10:06 AM
News IconHepatitis C Treatment Market is Appraised to be Valued USD 71.13 Bn by the End of 2024 (NASDAQ:KDMN)
pressreleaseping.com - December 8 at 6:44 PM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC - StreetInsider.com (NASDAQ:KDMN)
www.streetinsider.com - December 8 at 10:21 AM
streetinsider.com logoKadmon (KDMN) Issues Encouraging Update on Tesevatinib Phase 2 in NSCLC (NASDAQ:KDMN)
www.streetinsider.com - December 7 at 10:28 AM
streetinsider.com logoKadmon (KDMN) Submits ANDA for KD034 (NASDAQ:KDMN)
www.streetinsider.com - December 6 at 10:23 AM
News IconKadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Lepto... (NASDAQ:KDMN)
ih.advfn.com - December 6 at 10:23 AM
us.rd.yahoo.com logoKadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases (NASDAQ:KDMN)
us.rd.yahoo.com - December 6 at 10:23 AM
us.rd.yahoo.com logo8:31 am Kadmon Holdings announces data from its ongoing Phase 2 clinical study of tesevatinib for the treatment of epidermal growth factor receptor NSCLC that has metastasized to the brain and/or the leptomeninges (NASDAQ:KDMN)
us.rd.yahoo.com - December 6 at 10:23 AM
businesswire.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA - Business Wire (press release) (NASDAQ:KDMN)
www.businesswire.com - December 5 at 6:22 PM
finance.yahoo.com logo4:01 pm Kadmon Holdings submits ANDA for KD034 - first application submitted to the FDA for a generic trientine hydrochloride product for the treatment of Wilson's disease (NASDAQ:KDMN)
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA (NASDAQ:KDMN)
finance.yahoo.com - December 5 at 6:22 PM
finance.yahoo.com logoKadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference (NASDAQ:KDMN)
finance.yahoo.com - November 29 at 4:20 PM
businesswire.com logoKadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ... - Business Wire (press release) (NASDAQ:KDMN)
www.businesswire.com - November 21 at 10:56 AM
streetinsider.com logoForm 424B3 Kadmon Holdings, Inc. - StreetInsider.com (NASDAQ:KDMN)
www.streetinsider.com - November 21 at 10:56 AM
4-traders.com logoKADMON HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:KDMN)
www.4-traders.com - November 21 at 10:56 AM
streetinsider.com logoForm 424B3 Kadmon Holdings, Inc. (NASDAQ:KDMN)
www.streetinsider.com - November 21 at 10:56 AM
finance.yahoo.com logoKadmon to Present at the Jefferies 2016 London Healthcare Conference (NASDAQ:KDMN)
finance.yahoo.com - November 14 at 9:52 AM
streetinsider.com logoForm 8-K Kadmon Holdings, Inc. For: Nov 09 (NASDAQ:KDMN)
www.streetinsider.com - November 9 at 5:32 PM
businesswire.com logoKadmon Provides Business Update and Reports Third Quarter 2016 Financial Results (NASDAQ:KDMN)
www.businesswire.com - November 9 at 5:32 PM
publicnow.com logoKadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis (NASDAQ:KDMN)
www.publicnow.com - September 22 at 9:00 AM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:KDMN)
biz.yahoo.com - September 14 at 10:01 AM
finance.yahoo.com logoKadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016 (NASDAQ:KDMN)
finance.yahoo.com - September 7 at 5:56 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh (NASDAQ:KDMN)
biz.yahoo.com - September 7 at 5:56 PM
publicnow.com logoKadmon to Present at Two Upcoming Investor Conferences (NASDAQ:KDMN)
www.publicnow.com - September 7 at 9:13 AM
investopedia.com logoDan Loeb Owns 17% of Firm Founded by Sam Waksal (KDMN) (NASDAQ:KDMN)
www.investopedia.com - August 29 at 5:44 PM
biz.yahoo.com logoKADMON HOLDINGS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:KDMN)
biz.yahoo.com - August 29 at 5:44 PM
finance.yahoo.com logoKadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma (NASDAQ:KDMN)
finance.yahoo.com - August 29 at 10:20 AM
finance.yahoo.com logo'Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality,' H.C. Wainwright Says (NASDAQ:KDMN)
finance.yahoo.com - August 22 at 5:51 PM
finance.yahoo.com logoCiti Sees Kadmon's Trials As 'Risky,' Initiates With Neutral Rating (NASDAQ:KDMN)
finance.yahoo.com - August 22 at 5:51 PM
publicnow.com logoKadmon Data Published in Science Signaling Show ROCK2 Signaling as a Key Modulator of T Follicular Helper Cell Function in Autoimmune Diseases (NASDAQ:KDMN)
www.publicnow.com - August 11 at 6:05 PM
finance.yahoo.com logoDaniel Loeb Discloses Stake in Biopharma Startup Founded by Sam Waskal (NASDAQ:KDMN)
finance.yahoo.com - August 9 at 8:53 AM
News IconThird Point, Silver Point and GoldenTree See Potential In Kadmon Holdings (KDMN); Bearish Session for Bristol-Myers (BMY) (NASDAQ:KDMN)
galaxystocks.com - August 8 at 10:31 AM
insidermonkey.com logoThree Top Hedge Funds Disclose Positions in Kadmon Holdings (KDMN), Founded by Sam Waksal (NASDAQ:KDMN)
www.insidermonkey.com - August 8 at 10:30 AM
reuters.com logoKadmon Holdings Inc (KDMN.N) (NASDAQ:KDMN)
in.reuters.com - August 1 at 10:36 AM
finance.yahoo.com logoCoverage initiated on Kadmon Holdings by WBB Securities (NASDAQ:KDMN)
finance.yahoo.com - August 1 at 9:24 AM
247wallst.com logo4 More IPO Hopefuls for Week of August 1 (NASDAQ:KDMN)
247wallst.com - July 31 at 10:39 AM
News IconWaksal's Kadmon IPO crumbles after raising $75M (NASDAQ:KDMN)
www.fiercebiotech.com - July 29 at 11:55 AM
4-traders.com logoDrug Developer Kadmon Slumps in Trading Debut (NASDAQ:KDMN)
www.4-traders.com - July 29 at 11:55 AM
cnbc.com logoSam Waksal's Kadmon Holdings shares open below offering price in debut (NASDAQ:KDMN)
www.cnbc.com - July 29 at 11:55 AM
bizjournals.com logoShares of drug developer Kadmon slide, worrying investors (NASDAQ:KDMN)
www.bizjournals.com - July 29 at 11:55 AM
wsj.com logo[$$] Redemption on Offer as Disgraced Executive Sam Waksal’s Startup Launches IPO (NASDAQ:KDMN)
www.wsj.com - July 27 at 1:27 AM
wsj.com logo[$$] Redemption on Offer as Disgraced Executive Sam Waksal's Startup Launches IPO (NASDAQ:KDMN)
www.wsj.com - July 26 at 5:48 PM

Social

What is Kadmon Holdings' stock symbol?

Kadmon Holdings trades on the NASDAQ under the ticker symbol "KDMN."

Where is Kadmon Holdings' stock going? Where will Kadmon Holdings' stock price be in 2017?

5 analysts have issued 12-month price objectives for Kadmon Holdings' stock. Their forecasts range from $7.50 to $25.00. On average, they expect Kadmon Holdings' share price to reach $14.10 in the next twelve months.

When will Kadmon Holdings announce their earnings?

Kadmon Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, November, 9th 2016.

What are analysts saying about Kadmon Holdings stock?

Here are some recent quotes from research analysts about Kadmon Holdings stock:

  • According to Zacks Investment Research, "Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. " (1/11/2017)

  • Citigroup Inc. analysts commented, "We believe investors could find a better de-risked entry point in the next 12–18 months with more data as we see long term upside," analyst Robyn Karnauskas wrote in a note.Related Link: "Kadmon Offers A Diverse Clinical Pipeline, And Value Optionality," H.C. Wainwright Says"While we note 40–100 percent upside if every POC trial works, the stock could trade at $3–$5/sh (50–70 percent downside) if Tesevatinib fails in cancer trials & could trade at cash ($1/sh) if KD-025 also fails due to safety," the analyst continued.Karnauskas noted that the company may face cash crunch beyond first–second quarter of 2017 and they may be at risk of going to capital markets again before majority of data readout in the second half of 2017.That said, the analyst is positive on the Tesevatinib cancer program, as it crosses the blood brain barrier."We see FV of this program at $9/sh (75 percent of our valuation) and model 35 percent probability to brain met NSCLC opportunity ($400 million peak unadjusted) and 25 percent probability to GBM opportunity ($800 million peak unadjusted)," (8/22/2016)

Who owns Kadmon Holdings stock?

Kadmon Holdings' stock is owned by many different of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.90%), Anchorage Capital Group L.L.C. (0.28%), State Street Corp (0.16%) and Kingdon Capital Management L.L.C. (0.12%). Company insiders that own Kadmon Holdings stock include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.

Who bought Kadmon Holdings stock? Who is buying Kadmon Holdings stock?

Kadmon Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC and State Street Corp. Company insiders that have bought Kadmon Holdings stock in the last two years include Bart M Schwartz, Daniel S Loeb, Goldentree Asset Management Lp, Harlan Waksal and Konstantin Poukalov.

How do I buy Kadmon Holdings stock?

Shares of Kadmon Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kadmon Holdings stock cost?

One share of Kadmon Holdings stock can currently be purchased for approximately $3.59.

Kadmon Holdings (NASDAQ:KDMN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Earnings History Chart

Earnings by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Dividend History Chart

Dividend Payments by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Last Updated on 2/25/2017 by MarketBeat.com Staff